Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Mark on +44 1494 818 049 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Mark Denton
Managing Director
+44 1494 818 049

I have just secured my first position within the highly competitive medical sales industry, and I definitely could not have done it without the team at Zenopa's help.
Avril, 2012

AstraZeneca receives EU approval for Axanum

2 August 2011 00:00 in Pharmaceutical Company Product News

AstraZeneca's new drug Axanum has received a positive agreement of approval in 23 European Union member states and Norway.

The medicine was created to treat patients at high risk of cardiovascular events such as heart attack and stroke, while also offering protection against the development of gastric ulcers.

Axanum is a combination of low-dose aspirin and esomeprazole, the active ingredient in the Nexium drug.

Tony Zook, executive vice-president of AstraZeneca's global commercial organisation, welcomed the company's latest regulatory approval.

"We will now work with relevant health authorities to secure reimbursement decisions and get on to formularies to bring this medicine to patients as soon as possible," he said.

Last week, AstraZeneca announced that its revenue for the second quarter of the year was $8.43 million (5.18 million pounds), down by two percent from the corresponding period of 2010 on constant exchange rates.

However, chief executive David Brennan noted that the firm's blood-thinning drug Brilinta has now been approved for sale in 41 countries. ADNFCR-8000103-ID-800673595-ADNFCR

Other news stories from 02/08/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2014 Zenopa Ltd